18349-09-2Relevant articles and documents
POLYCYCLIC COMPOUND AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE POLYCYCLIC COMPOUND OR THE COMPOSITION
-
Page/Page column 274, (2020/11/03)
Specific polycyclic compounds, a material for an organic electroluminescence device comprising said specific polycyclic compound, an organic electroluminescence device comprising said specific polycyclic compound, an electronic equipment comprising said organic electroluminescence device, a process for preparing said polycyclic compounds, and the use of said polycyclic compounds in an organic electroluminescence. (Formula I) (I)
NOVEL ANTIBIOTICS AND METHODS OF USING SAME
-
Page/Page column 72, (2018/05/16)
The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subjec
Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA)
Gopalsamy, Ariamala,Narayanan, Arjun,Liu, Shenping,Parikh, Mihir D.,Kyne, Robert E.,Fadeyi, Olugbeminiyi,Tones, Michael A.,Cherry, Jonathan J.,Nabhan, Joseph F.,LaRosa, Gregory,Petersen, Donna N.,Menard, Carol,Foley, Timothy L.,Noell, Stephen,Ren, Yong,Loria, Paula M.,Maglich-Goodwin, Jodi,Rong, Haojing,Jones, Lyn H.
, p. 3094 - 3108 (2017/04/21)
The C-5 substituted 2,4-diaminoquinazoline RG3039 (compound 1), a member of a chemical series that was identified and optimized using an SMN2 promoter screen, prolongs survival and improves motor function in a mouse model of spinal muscular atrophy (SMA).